The FDA’s Peripheral and Central Nervous System (PCNS) Advisory Committee recently met to discuss Eli Lilly’s donanemab as a potential treatment for early Alzheimer’s disease. The committee looked at the trial design and safety signals of the drug, ultimately voting unanimously in favor of its risk-benefit profile. If donanemab is approved, it could help alleviate regulatory uncertainty surrounding treatments for Alzheimer’s disease.
June 19, 2024
Artificial Intelligence
FDAcop
